Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of AER-271 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of AER-271 in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AER-271 (Primary)
  • Indications Brain oedema
  • Focus Adverse reactions; First in man
  • Sponsors Aeromics

    • Most Recent Events

    • 26 Jul 2018 New trial record
    • 09 Jul 2018 According to an Aeromics media release, the data obtained in this study will be used to inform the design of planned phase 2 trial in severe ischemic stroke patients with Large Hemispheric Infarction (LHI).
    • 09 Jul 2018 According to an Aeromics media release, the first cohort was dosed on June 26, 2018 and company expects to complete the trial in May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top